| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Duvoglustat hydrochloride (1-Deoxynojirimycin; AT-2220; Moranoline; deoxynojirimycin; DNJ) is a novel and potent alpha-glucosidase inhibitor found in mulberry leaves and has antihyperglycemic, anti-obesity, and antiviral activities. Duvoglustat works as an antihyperglycemic agent by slowing the rate at which carbohydrates break down into monosaccharides, which can prevent the rise in postprandial hyperglycemia.
| ln Vivo |
Duvoglustat hydrochloride (1-Deoxynojirimycin hydrochloride) (20-80 mg/kg; i.v.; daily for four weeks) shows anti-obesity effect [3].
Duvoglustat hydrochloride significantly improves insulin sensitivity via activating insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice[3].
|
|---|---|
| Animal Protocol |
db/db mice
20, 40, 80 mg/kg Intravenously; daily for four weeks |
| References |
|
| Additional Infomation |
AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). GAA to the lysosome, where it can perform its normal function. AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA.
An alpha-glucosidase inhibitor with antiviral action. Derivatives of deoxynojirimycin may have anti-HIV activity. Drug Indication Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a relatively rare neuromuscular and lysosomal storage disorder caused by inherited genetic mutations in a key enzyme called α-glucosidase (Gaa). Mechanism of Action AT2220 is designed to act as a pharmacological chaperone by selectively binding to the misfolded enzyme responsible for Pompe disease, Gaa. After binding to the enzyme, it is thought that AT2220 promotes the proper folding, processing, and trafficking of the enzyme from the endoplasmic reticulum to its final destination, the lysosome, the area of the cell where the enzyme does its work. Once it reaches the lysosome, the pharmacological chaperone is displaced, and the enzyme can perform its normal function, which is the breakdown of its natural substrate, glycogen. |
| Molecular Formula |
C6H14CLNO4
|
|---|---|
| Molecular Weight |
199.631
|
| Exact Mass |
199.061
|
| Elemental Analysis |
C, 36.10; H, 7.07; Cl, 17.76; N, 7.02; O, 32.06
|
| CAS # |
73285-50-4
|
| Related CAS # |
1-Deoxynojirimycin;19130-96-2
|
| PubChem CID |
13018787
|
| Appearance |
White to off-white solid powder
|
| Density |
1.456 g/cm3
|
| Boiling Point |
361.1ºC at 760 mmHg
|
| Melting Point |
195-196ºC
|
| Flash Point |
197.3ºC
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
12
|
| Complexity |
132
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O
|
| InChi Key |
ZJIHMALTJRDNQI-VFQQELCFSA-N
|
| InChi Code |
InChI=1S/C6H13NO4.ClH/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H21H/t3-,4+,5-,6-/m1./s1
|
| Chemical Name |
(2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride
|
| Synonyms |
Duvoglustat; BAY-h 5595; AT2220; AT-2220; AT 2220; DNJ; 1DNJ; NOJ; Moranoline; Moranolin; Duvoglustat hydrochloride; deoxynojirimycin; 1-Deoxynojirimycin; 1-Deoxy-Nojirimycin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~1252.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0093 mL | 25.0463 mL | 50.0927 mL | |
| 5 mM | 1.0019 mL | 5.0093 mL | 10.0185 mL | |
| 10 mM | 0.5009 mL | 2.5046 mL | 5.0093 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01380743 | Completed | Drug: duvoglustat Drug: rhGAA |
Pompe Disease | Amicus Therapeutics | October 31, 2011 | Phase 2 |
| NCT01489995 | Completed | Drug: A (migalastat) Drug: B (migalastat) |
Fabry Disease | Amicus Therapeutics | October 2011 | Phase 1 |
| NCT03832452 | Completed | Other: Placebo Drug: Moxifloxacin |
Healthy | Idorsia Pharmaceuticals Ltd. | February 14, 2019 | Phase 1 |
| NCT01822028 | Completed | Drug: Treatment A Drug: Treatment B |
Diarrhea | Actelion | March 2013 | Phase 1 |
| NCT01853852 | Completed | Other: Potable water Drug: Placebo capsule |
Fabry Disease | Amicus Therapeutics | September 2011 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
